Each filer's latest filing for 03237H101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
FMR LLC
13G/A
|
15.0% |
2/5/2026
Event 12/31/2025
|
||
| FMR LLC | 15.0% | |||
| Abigail P. Johnson | 15.0% | |||
|
Perceptive Advisors LLC
13G/A
|
8.2% |
11/16/2026
Event 9/30/2026
|
||
| Perceptive Advisors LLC | 8.2% | |||
| Joseph Edelman | 8.2% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 8.2% | |||
| BlackRock, Inc. 13G/A | 7.1% |
1/21/2026
Event 12/31/2025
|
||
|
TCG Crossover GP II, LLC
13G/A
|
5.7% |
2/17/2026
Event 12/31/2025
|
||
| TCG Crossover GP II, LLC | 5.7% | |||
| TCG Crossover Fund II, L.P. | 5.7% | |||
| Chen Yu | 5.7% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (5) | ||||
|
Point72 Asset Management, L.P.
13G/A
|
2.6% |
11/14/2025
Event 9/30/2025
|
||
| Point72 Asset Management, L.P. | 2.6% | |||
| Point72 Capital Advisors, Inc. | 2.6% | |||
| Steven A. Cohen | 2.6% | |||
|
Panacea Innovation Ltd
13G/A
|
2.6% |
2/14/2025
Event 12/31/2024
|
||
| Panacea Venture Healthcare Fund II, L.P. | 2.6% | |||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 2.6% | |||
| Panacea Innovation Limited | 2.6% | |||
| James Huang | 2.6% | |||
|
Adage Capital Management, L.P.
13G/A
|
2.5% |
2/12/2026
Event 12/31/2025
|
||
| Adage Capital Management, L.P. | 2.5% | |||
| Robert Atchinson | 2.5% | |||
| Phillip Gross | 2.5% | |||
|
Commodore Capital LP
13G/A
|
1.6% |
11/16/2026
Event 9/30/2026
|
||
| Commodore Capital LP | 1.6% | |||
| Commodore Capital Master LP | 1.6% | |||
| Robert Egen Atkinson | 1.6% | |||
| Michael Kramarz | 1.6% | |||
| Vanguard Group Inc 13G/A | 0% |
3/26/2026
Event 3/13/2026
|
||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 231 | 132 M | $3.85B |
| 2026 Q2 | 207 | 115 M | $2.07B |
| 2026 Q1 | 173 | 114 M | $1.59B |
| 2025 Q4 | 182 | 112 M | $1.36B |
| 2025 Q3 | 173 | 110 M | $1.49B |
| 2025 Q2 | 132 | 81.7 M | $524M |
| 2025 Q1 | 137 | 73.9 M | $262M |
| 2024 Q4 | 126 | 49.8 M | $188M |
| 2024 Q3 | 116 | 43.5 M | $141M |
| 2024 Q2 | 124 | 43.6 M | $82.9M |
| 2024 Q1 | 153 | 49.5 M | $141M |
| 2023 Q4 | 185 | 60.3 M | $887M |
| 2023 Q3 | 176 | 58.9 M | $1.08B |
| 2023 Q2 | 159 | 54.5 M | $1.18B |
| 2023 Q1 | 155 | 51.4 M | $1.51B |
| 2022 Q4 | 137 | 48.6 M | $1.79B |
| 2022 Q3 | 103 | 37.3 M | $1.05B |
| 2022 Q2 | 83 | 26.6 M | $513M |
| 2022 Q1 | 73 | 23.4 M | $300M |